Trials / Terminated
TerminatedNCT02855411
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether PF-04958242 is safe and effective in the treatment of cognitive dysfunction in schizophrenia subjects
Detailed description
This study was previously posted by Pfizer, Inc. Sponsorship of the trial was transferred to Biogen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-04958242 | Administered as specified in the treatment arm |
| DRUG | placebo | placebo, twice daily (BID) for 12 weeks, capsule |
Timeline
- Start date
- 2016-08-29
- Primary completion
- 2016-09-26
- Completion
- 2016-09-26
- First posted
- 2016-08-04
- Last updated
- 2020-01-09
- Results posted
- 2017-10-04
Locations
16 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02855411. Inclusion in this directory is not an endorsement.